Active, not recruitingPhase 3NCT05814627

Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis

Studying NON RARE IN EUROPE: Rheumatoid arthritis

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
AbbVie
Principal Investigator
ABBVIE INC.
AbbVie
Intervention
Upadacitinib(drug)
Enrollment
487 enrolled
Eligibility
18 years · All sexes
Timeline
20232026

Study locations (30)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT05814627 on ClinicalTrials.gov

Other trials for NON RARE IN EUROPE: Rheumatoid arthritis

Additional recruiting or active studies for the same condition.

See all trials for NON RARE IN EUROPE: Rheumatoid arthritis

← Back to all trials